Ibex Investors’s Cytokinetics CYTK Stock Holding History

Ibex Investors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-20,549	Closed	-$231	–	67
2019 Q2	$231	Buy	+20,549	New	+$198K	0.02%	61

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ibex Investors's CYTK Position: Q3 2019 in Review

Ibex Investors sold out of Cytokinetics (CYTK) in Q3 2019, closing a stake of 20,549 shares — an estimated $231 sold.

Ibex Investors first reported a position in CYTK in Q2 2019 and held it in 1 quarter. The position peaked at $231 in Q2 2019. 148 funds tracked by Wall St. Rank hold CYTK as of Q3 2019.

Ibex Investors reported no remaining Cytokinetics position as of Q3 2019 after selling out during the quarter.
Ibex Investors sold 20,549 Cytokinetics shares in Q3 2019, an estimated $231.
Ibex Investors first reported a position in Cytokinetics in Q2 2019 and held it in 1 quarter.
Ibex Investors's Cytokinetics position peaked at $231 in Q2 2019.
148 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2019.

Based on Ibex Investors's 13F filing for Q3 2019, filed 1 Nov 2019.